MEI Pharma, Inc. (MEIP): Price and Financial Metrics
MEIP Price/Volume Stats
| Current price | $3.20 | 52-week high | $7.97 |
| Prev. close | $3.25 | 52-week low | $3.20 |
| Day low | $3.20 | Volume | 16,466 |
| Day high | $3.44 | Avg. volume | 23,645 |
| 50-day MA | $4.05 | Dividend yield | N/A |
| 200-day MA | $5.80 | Market Cap | 21.32M |
MEIP Stock Price Chart Interactive Chart >
MEI Pharma, Inc. (MEIP) Company Bio
MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company was founded in 2000 and is based in San Diego, California.
Latest MEIP News From Around the Web
Below are the latest news stories about MEI PHARMA INC that investors may wish to consider to help them evaluate MEIP as an investment opportunity.
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023SAN DIEGO, December 11, 2023--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced clinical data from the monotherapy dose escalation stage of the ongoing Phase 1 study evaluating voruciclib, a selective oral cyclin-dependent kinase 9 ("CDK9") inhibitor, alone and in combination with venetoclax (Venclexta®), a B-cell lymphoma 2 ("BCL2") inhibitor, in p |
11 Cheapest Stocks With Biggest UpsideIn this piece, we will take a look at the 11 cheapest stocks with the biggest upside. If you want to skip our introduction to stock valuation and recent market news, then take a look at 5 Cheapest Stocks With Biggest Upside. Identifying the right stocks to invest in is a science that involves evaluating […] |
AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast CancerAstraZeneca's (AZN) capivasertib gets approval in combination with Faslodex for HR-positive, HER2-negative metastatic breast cancer. |
Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume RisesIronwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line. |
MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational HighlightsSAN DIEGO, November 09, 2023--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the quarter ended September 30, 2023 and highlighted recent corporate events. |
MEIP Price Returns
| 1-mo | -16.45% |
| 3-mo | -35.22% |
| 6-mo | -53.69% |
| 1-year | -35.59% |
| 3-year | -95.27% |
| 5-year | -94.52% |
| YTD | -44.83% |
| 2023 | 19.05% |
| 2022 | -90.88% |
| 2021 | 1.14% |
| 2020 | 6.45% |
| 2019 | -6.06% |
Continue Researching MEIP
Want to see what other sources are saying about MEI Pharma Inc's financials and stock price? Try the links below:MEI Pharma Inc (MEIP) Stock Price | Nasdaq
MEI Pharma Inc (MEIP) Stock Quote, History and News - Yahoo Finance
MEI Pharma Inc (MEIP) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...